{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:43Z","timestamp":1787009443341,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) complements nucleic acid tests for patient diagnosis and enables monitoring of population susceptibility to inform the coronavirus disease 2019 (COVID-19) pandemic response. It is important to understand the reliability of assays with different antigen or antibody targets to detect humoral immunity after SARS-CoV-2 infection and to understand how antibody (Ab) binding assays compare to those detecting neutralizing antibody (nAb), particularly as we move into the era of vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the performance of 6 commercially available enzyme-linked immunosorbent assays (ELISAs), including a surrogate virus neutralization test (sVNT), for detection of SARS-CoV-2 immunoglobulins (IgA, IgM, IgG), total or nAb. A result subset was compared with a cell culture\u2013based microneutralization (MN) assay. We tested sera from patients with prior reverse transcription polymerase chain reaction\u2013confirmed SARS-CoV-2 infection, prepandemic sera, and potential cross-reactive sera from patients with other non-COVID-19 acute infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For sera collected &amp;gt;14 days post\u2013symptom onset, the assay achieving the highest sensitivity was the Wantai total Ab at 100% (95% CI, 94.6%\u2013100%), followed by 93.1% for Euroimmun NCP-IgG, 93.1% for GenScript sVNT, 90.3% for Euroimmun S1-IgG, 88.9% for Euroimmun S1-IgA, and 83.3% for Wantai IgM. Specificity for the best-performing assay was 99.5% for the Wantai total Ab, and for the lowest-performing assay it was 97.1% for sVNT (as per the Instructions for Use [IFU]). The Wantai Total Ab had the best agreement with MN at 98% followed by Euroimmun S1-IgA, Euro NCP-IgG, and sVNT (as per IFU) with 97%, 97% and 95%, respectively; Wantai IgM had the poorest agreement at 93%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Performance characteristics of the SARS-CoV-2 serology assays detecting different antibody types are consistent with those found in previously published reports. Evaluation of the surrogate virus neutralization test in comparison to the Ab binding assays and a cell culture\u2013based neutralization assay showed good result correlation between all assays. However, correlation between the cell-based neutralization test and some assays detecting Ab\u2019s not specifically involved in neutralization was higher than with the sVNT. This study demonstrates the reliability of different assays to detect the humoral immune response following SARS-CoV-2 infection, which can be used to optimize serological test algorithms for assessing antibody responses post\u2013SARS-CoV-2 infection or vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofab239","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T14:56:01Z","timestamp":1620658561000},"source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6585-7150","authenticated-orcid":false,"given":"Suellen","family":"Nicholson","sequence":"first","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Karapanagiotidis","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arseniy","family":"Khvorov","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Douros","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mordant","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"},{"name":"WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bond","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"},{"name":"Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Druce","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"},{"name":"Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"},{"name":"Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-1726","authenticated-orcid":false,"given":"Damian","family":"Purcell","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R","family":"Lewin","sequence":"additional","affiliation":[{"name":"The Peter Doherty Institute for Infection and Immunity, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia"},{"name":"Victorian Infectious Diseases Service, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"},{"name":"Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Sullivan","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"},{"name":"WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Catton","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"2021102115002681900_CIT0001","author":"European Centre for Disease Prevention and Control"},{"key":"2021102115002681900_CIT0002","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral immune response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"N Engl J Med"},{"key":"2021102115002681900_CIT0003","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"2021102115002681900_CIT0004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/22221751.2020.1729071","article-title":"Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2021102115002681900_CIT0005"},{"key":"2021102115002681900_CIT0006","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(20)30273-5","article-title":"Connecting clusters of COVID-19: an epidemiological and serological investigation","volume":"20","author":"Yong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021102115002681900_CIT0007","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1473-3099(20)30198-5","article-title":"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study","volume":"20","author":"Qiu","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021102115002681900_CIT0008","volume-title":"Evaluation of sensitivity and specificity of four commercially available SARS-CoV-2 antibody immunoassays","author":"Public Health England, Porton Down, Nuffield Department of Medicine, University of Oxford, Oxford University Hospitals NHS Foundation Trust","year":"2020"},{"key":"2021102115002681900_CIT0009","author":"Halters Associates"},{"key":"2021102115002681900_CIT0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2020.06.012","article-title":"The COVID-19 Serology Studies Workshop: recommendations and challenges","volume":"53","author":"Lerner","year":"2020","journal-title":"Immunity"},{"key":"2021102115002681900_CIT0011","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25:2000045","author":"Corman","year":"2020","journal-title":"Euro Surveill"},{"key":"2021102115002681900_CIT0012","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jiaa467","article-title":"Evaluation of serological tests for SARS-CoV-2: implications for serology testing in a low-prevalence setting","volume":"222","author":"Bond","year":"2020","journal-title":"J Infect Dis"},{"key":"2021102115002681900_CIT0013","doi-asserted-by":"crossref","first-page":"1 557","DOI":"10.1093\/infdis\/jiw080","article-title":"Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection","volume":"213","author":"Houser","year":"2016","journal-title":"J Infect Dis"},{"key":"2021102115002681900_CIT0014","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1128\/JVI.78.7.3572-3577.2004","article-title":"Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice","volume":"78","author":"Subbarao","year":"2004","journal-title":"J Virol"},{"key":"2021102115002681900_CIT0015","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"key":"2021102115002681900_CIT0016","author":"Ralph Scherer","year":"2018"},{"key":"2021102115002681900_CIT0017","author":"Victorian COVID-19 data."},{"key":"2021102115002681900_CIT0018","article-title":"Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients","author":"Isho","year":"2020","journal-title":"medRxiv"},{"key":"2021102115002681900_CIT0019","article-title":"Evaluation of nine commercial SARS-C0V-2 immunoassays","author":"Lassauniere","year":"2020","journal-title":"medRxiv"},{"key":"2021102115002681900_CIT0020","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/22221751.2020.1780951","article-title":"Serological differentiation between COVID-19 and SARS infections","volume":"9","author":"Wang","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2021102115002681900_CIT0021","first-page":"1073","article-title":"A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nature"},{"key":"2021102115002681900_CIT0022","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1038\/s41467-020-17317-y","article-title":"An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment","volume":"11","author":"GeurtsvanKessel","year":"2020","journal-title":"Nat Commun"},{"key":"2021102115002681900_CIT0023","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2021102115002681900_CIT0024","doi-asserted-by":"crossref","first-page":"1557.e1","DOI":"10.1016\/j.cmi.2020.07.038","article-title":"Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs","volume":"26","author":"Van Elslande","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2021102115002681900_CIT0025","article-title":"Humoral response dynamics following infection with SARS-CoV-2","author":"Grandjean","year":"2020","journal-title":"medRxiv"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab239\/37904100\/ofab239.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab239\/40807885\/ofab239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab239\/40807885\/ofab239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T11:03:42Z","timestamp":1634814222000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab239\/6273226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab239","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.01.21.21250249","asserted-by":"object"}]},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,5,10]]},"article-number":"ofab239"}}